The Burlingame, Calif., company announced the filing of the effectiveness section as part of Zimeta’s New Animal Drug Application (NADA). All remaining technical sections were expected to be submitted to the U.S. Food and Drug Administration by the end of March.
It’s potentially good news for equine practitioners.
“Dipyrone will be very familiar to seasoned veterinarians,” said Peter Morresey, BVSc, Dipl. ACVIM, Dipl. ACT, a veterinarian with Rood and Riddle Equine Hospital in Lexington, Ky. “While never approved in the United States, dipyrone enjoyed widespread usage for control of fever and pain before withdrawal from the market in 1995.
“If approved, it will be available again in the United States in an FDA-approved formulation,” Dr. Morresey added.
In other news, a field test using 32 cats showed the effectiveness and safety of KIND-010 for the stimulation of weight gain in cats under clinical conditions.
At the second week of the field study, the mean weight of cats in the KIND-010 group increased by 3.25 percent while those in the placebo group showed a negative weight gain of 1.65 percent. The mean weight of cats in the KIND-010 group was 9.5 pounds, compared with 8.8 pounds in the control group.
Kindred also reported that the pivotal effectiveness study for KIND-010 for the management of weight loss in cats is more than halfway enrolled.
The KB105 study will enroll a minimum of 200 cats to assess the mean percent change in body weight from Day 1 to Week 2.
“Weight loss in cats is a major unmet medical need, and we look forward to further progress,” said Richard Chin, M.D., Kindred’s president and CEO.
Originally published in the April 2016 issue of Veterinary Practice News. Did you enjoy this article? Then subscribe today!